Market Overview

UPDATE: Credit Suisse Upgrades Ironwood Pharmaceuticals to Outperform on Positive Linzess Survey

Related IRWD
AcelRx Pharmaceuticals (ACRX) Jumps: Stock Adds 11.7% in Session - Tale of the Tape
Conferences/Events Scheduled for Week of Jun. 9th to Jun. 13th

Credit Suisse upgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Neutral to Outperform and raised the price target from $15.00 to $24.00.

Credit Suisse analyst Catherine Arnold commented, "CS proprietary market research survey with ~100 physicians implies greater demand via both category expansion and competitive market share. Respondents include 55% gastroenterologists and 45% PCPs, ~70% who were early Linzess users, and all with brand awareness."

Ironwood Pharmaceuticals closed at $17.68 on Thursday.

Posted-In: Credit SuisseAnalyst Color Upgrades Analyst Ratings

 

Related Articles (IRWD)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters